Sanofi has agreed to buy cancer biotech company Synthorx for $2.5 billion, the first big move by new Chief Executive Paul Hudson to reinvigorate the sprawling French health-care giant.
The company has a long history in cancer-drug development but has fallen behind in the latest rush to develop immunotherapies, or drugs that help the immune system fight tumors. Its acquisition of Synthorx is a bet that it can make up that ground.
Synthorx, based in La Jolla, Calif., is developing a drug that aims to boost the immune system’s response to cancer. The drug is in the early phase of human testing in a range of cancers, both on its own and in combination with existing cancer immunotherapies. Sanofi on Monday said it would pay $68 a share in cash for Synthorx, a 172% premium to the smaller company’s closing share price Friday.
“This acquisition fits perfectly with our strategy to build a portfolio of high-quality assets and to lead with innovation,” said Mr. Hudson, who is set to provide an eagerly awaited strategy update to investors Tuesday.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Throws the Bag: Tapestry’s Capri Deal Blocked Over Market Monopoly Concerns
Apr 22, 2024 by
CPI
Italy’s Antitrust Authority Investigates Enel’s Communication of Energy Price Hikes
Apr 22, 2024 by
CPI
UK Data Regulator Uncovers Flaws in Google’s Privacy Sandbox Proposal
Apr 22, 2024 by
CPI
Japan’s Antitrust Body Orders Google to Amend Ad Search Practices
Apr 22, 2024 by
CPI
Senator Blackburn Blasts Ticketmaster Amid DOJ Probe
Apr 22, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI